AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared
AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.
How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
Is this the end of EMFACE lookalikes? Inside BTL’s cross-border IP enforcement playbook
BTL’s EMFACE wins global IP battle against WonderFace. Find out how this reshapes the energy-based facial therapy market in 2026.